Recent Finacing
Recent Raise
Convergen is a Suzhou-based biotech developing TrimTAC, a TRIM21-leveraged targeted protein degradation platform aimed at clearing pathogenic protein aggregates in neurodegenerative disorders.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Convergen.
